Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Robert A. Bonomo

Robert is chief of the medical service and director of the VISN 10 GRECC at the Cleveland VA Medical Center, and is professor of medicine, pharmacology, molecular biology and microbiology, biochemistry, proteomics and bioinformatics at Case Western Reserve University School of Medicine, Cleveland, Ohio, United States.

Contact Info

Email:
robert.bonomo@va.gov

Recent stories

  • Micrograph of Acinetobacter baumannii bacteria

    Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitorSubscription

    10 MAY 2017

    Over the past decade, infections caused by multidrug-resistant Gram-negative organisms have increased. The limited availability in treatment options for these infections prompted both the UK to create a five-year antimicrobial resistance strategic plan to stimulate the development of new antibiotics, and the Infectious Diseases Society of America to call for ten new antimicrobial agents to be developed by 2020. Ceftazidime-avibactam is a combination of a third-generation cep

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.